Samsung Bioepis Presents Five-Year Follow-Up Results of SB3 (biosimilar, trastuzumab) in P-III Study for Breast Cancer at SABCS 2021
Shots:
- The company reported the 5yr. follow up results of P-III study evaluating SB3 (trastuzumab biosimilar) vs trastuzumab in 875 patients with HER2-positive early or LA breast cancer for 4yrs. post randomization
- The results showed comparable long-term survival results b/w SB3 and trastuzumab after a median follow-up of 68mos. In 5yrs. survival analysis, EFS rate (79.8% & 75.0%), 5yrs. OS was also comparable with OS rate (92.5% & 85.4%)
- In the post-hoc analysis, SB3 was compared with non-drifted trastuzumab which showed an EFS rate (79.8% vs 82.5%), OS rate (92.5% & 91.4%). SB3 was approved in the US under the brand name Ontruzant & is marketed by Organon
Ref: Globe Newswire | Image: Samsung Bioepis
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
